096 Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects With Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study

Journal of Neurology, Neurosurgery and Psychiatry - United Kingdom
doi 10.1136/jnnp-2019-anzan.84
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Pnd141 - Characteristics and Management of Migraine Patients Who Have Failed Prior Preventive Treatment in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

An Open-Label Pilot Study on the Efficacy and Tolerability of Levetiracetam in the Prophylaxis of Migraine

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2003English

Pnd67 - Are New Preventive Migraine Drugs Cost-Effective for Patients With Chronic and Episodic Migraine for Whom Other Preventive Medications Had Failed?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy of Pregabalin Versus Nortriptyline in the Treatment of Chronic Low Backache With Radiculopathy: An Open Label Observational Study

International Journal of Basic & Clinical Pharmacology
2019English

The Liberty of Open Access

PLAID: People Living with And Inspired by Diabetes
2017English

Ineffective Acute Treatment of Episodic Migraine Is Associated With New-Onset Chronic Migraine

Neurology
Neurology
2015English

Fremanezumab for Preventive Treatment of Migraine

Neurology
Neurology
2018English

Efficacy and Tolerability of Escitalopram in Treatment of Major Depressive Disorder With Anxiety Symptoms: A 24-Week, Open-Label, Prospective Study in Chinese Population

Neuropsychiatric Disease and Treatment
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy